NATHAN FOWLER to Lymphoma
This is a "connection" page, showing publications NATHAN FOWLER has written about Lymphoma.
Connection Strength
1.790
-
Umbralisib, a Dual PI3Kd/CK1e Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021 05 20; 39(15):1609-1618.
Score: 0.406
-
Idelalisib in the management of lymphoma. Blood. 2016 07 21; 128(3):331-6.
Score: 0.291
-
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015 May 21; 125(21):3357-9.
Score: 0.271
-
Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma. Ophthalmic Plast Reconstr Surg. 2019 May/Jun; 35(3):243-246.
Score: 0.089
-
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346.
Score: 0.088
-
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018 11 16; 6(1):119.
Score: 0.086
-
The landscape of new drugs in lymphoma. Nat Rev Clin Oncol. 2017 Jun; 14(6):335-346.
Score: 0.076
-
Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol. 2017 12; 179(5):851-854.
Score: 0.074
-
Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506.
Score: 0.073
-
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015 Nov 18; 7(314):314ra185.
Score: 0.070
-
Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiat Oncol. 2015 Sep 25; 10:206.
Score: 0.069
-
Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol. 2015 Sep; 27(5):384-91.
Score: 0.069
-
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015 Nov; 171(4):463-70.
Score: 0.069
-
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):99-105.
Score: 0.057